Lack of evidence for increased inhibitor incidence in patients switched from plasma‐derived to recombinant factor VIII

This publication has 16 references indexed in Scilit:

• High responding factor VIII inhibitors in mild Haemophilia - is there a link with recent changes in clinical practice?
  Haemophilia, 2000
• Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
  Thrombosis and Haemostasis, 2000
• Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates
  Haemophilia, 1999
• Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates
  Blood Coagulation & Fibrinolysis, 1999
• Inhibitor Development in a Multitransfused Patient with Severe Haemophilia A
  Thrombosis and Haemostasis, 1999
• Is a Change of Factor VIII Product a Risk Factor for the Development of a Factor VIII Inhibitor?
  Thrombosis and Haemostasis, 1998
• A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A
  Thrombosis and Haemostasis, 1997
• A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A
  Thrombosis and Haemostasis, 1997
• A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group
  Blood, 1993
• Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
  New England Journal of Medicine, 1990